Taha Koray Sahin
@tkoraysahin.bsky.social
Department of Medical Oncology, Hacettepe University
Reposted by Taha Koray Sahin
🧬 Cell therapy in sarcoma: what do we know so far?
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Cell therapy in sarcoma: current landscape and future directions
Sarcomas are rare malignancies of mesenchymal origin, characterized by significant biological and clinical heterogeneity. Many subtypes demonstrate limited sensitivity to standard systemic treatments,...
jitc.bmj.com
January 12, 2026 at 5:28 PM
🧬 Cell therapy in sarcoma: what do we know so far?
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social
Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.
@tkoraysahin.bsky.social @lizconnolly.bsky.social